Booz Allen Hamilton Closes $720M Deal as Organic Revenue Drops 4%

NEW YORK, August 24 —

Booz Allen Hamilton Holding Cor (BAH) closed its $720mn acquisition of Ultra I&C Mission Solutions with organic revenue running 4.2% below year-ago levels.

$720mn to Buy Growth BAH's Organic Revenue Isn't Delivering

TTM revenue stands at $11.1bn, down 4.2% YoY. Cyclical softness is normal for a defense IT shop running multi-year government contracts, but closing a deal of that size into that decline signals the board doesn't expect organic recovery to carry the load. The Ultra I&C acquisition is as much a statement about BAH's internal trajectory as it is about capability.

Ultra I&C specializes in intelligence and communications systems for defense customers, precisely the segment where Pentagon modernization spending is accelerating. BAH is buying access to a contract pipeline it previously couldn't compete for.

BAH's Annual Free Cash Flow Exceeds the Entire Acquisition Price

At $861mn in trailing FCF against that deal price, BAH generated more cash over the past twelve months than it just wrote on this check. That ratio limits balance sheet risk and keeps capital allocation options intact. No leverage heroics required.

FCF is a trailing figure, however. Defense acquisitions of this scale carry integration charges, workforce overlap costs, and contract re-scoping expenses that won't appear until the next earnings call. A stress test on integration timing is worth running through the DCF calculator before taking a position.

11.3x Forward Earnings With a 39% Valuation Gap the Market Hasn't Closed

The four-day losing streak that preceded this close is visible in the chart. At $75.83 and 11.3x forward P/E, one independent valuation model puts intrinsic value 39.4% above the market price. That gap only closes if integration goes cleanly and combined revenue inflects positively.

The market's skepticism is not irrational. A 4.2% organic revenue decline alongside a large acquisition is the setup for estimate cuts if execution slips. The discount is real; so is the risk that earned it.

Two Quarters to Prove the Acquisition Was Worth It

The thesis gets its first test at the next earnings call: Ultra I&C revenue contribution and integration cost guidance. If combined revenue doesn't turn positive YoY within two quarters, the valuation gap won't close; the market will simply extend the organic-decline discount to the combined entity.

The specific number to watch: whether management gives a concrete accretion timeline with a margin target attached. A vague "strategic value" answer should read as bearish. A quantified revenue ramp is the tell that the deal was priced correctly. That is the number that will prove the thesis wrong.

Generate a full BAH valuation model, including earnings forecasts and sector comps, at Basis Report's BAH stock intelligence page.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.